Lead Product(s) : JAG201
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Jaguar Gene Therapy to Start Pediatric Trial for ASD and Phelan-McDermid Syndrome
Details : JAG201 is an investigational gene replacement therapy for autism with SHANK3 mutations or deletions, administered via a one-time unilateral ICV injection, targeting the entire brain and spinal cord.
Product Name : JAG201
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
September 07, 2024
Lead Product(s) : JAG201
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : JAG201
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Jaguar Gene Therapy Clears IND for JAG201 in Autism Spectrum Disorder
Details : JAG201 is in preclinical studies for SHANK3-mutated autism and Phelan-McDermid syndrome, delivering SHANK3 via AAV9 vector.
Product Name : JAG201
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
January 31, 2024
Lead Product(s) : JAG201
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol,Cannamide
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Negev Autism Center Soroka University Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
SciSparc to Commence its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
Details : SCI-210 is a proprietary combination of cannabidiol (CBD), a non-psychoactive cannabinoid, and PEA, clinical trial will investigate SCI-210 in comparison to CBD monotherapy in treating ASD.
Product Name : SCI-210
Product Type : Controlled Substance
Upfront Cash : Inapplicable
July 14, 2023
Lead Product(s) : Cannabidiol,Cannamide
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Negev Autism Center Soroka University Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol,Cannamide
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SCI-210 is a proprietary combination of cannabidiol (CBD), a non-psychoactive cannabinoid, and PEA, clinical trial will investigate SCI-210 in comparison to CBD monotherapy in treating ASD.
Product Name : SCI-210
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 18, 2023
Lead Product(s) : Cannabidiol,Cannamide
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol,Cannamide
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The trial's objectives are to evaluate the safety, tolerability and efficacy of SCI-210 (cannabidiol) in children and adolescents with ASD in a designed 20-week, randomized, double-blind, placebo controlled with a cross-over clinical trial of 60 children...
Product Name : SCI-210
Product Type : Controlled Substance
Upfront Cash : Inapplicable
August 08, 2022
Lead Product(s) : Cannabidiol,Cannamide
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : IBC-Ab002
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : National Institute on Aging
Deal Size : $5.0 million
Deal Type : Funding
Details : The grant will be used to support the first-in-human clinical study of IBC-Ab002, a proprietary anti-PD-L1 antibody developed and engineered with differentiating characteristics tailored for the treatment of Alzheimer’s disease.
Product Name : IBC-Ab002
Product Type : Antibody
Upfront Cash : Undisclosed
August 27, 2021
Lead Product(s) : IBC-Ab002
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : National Institute on Aging
Deal Size : $5.0 million
Deal Type : Funding